Sources checked November 20, 2026.
What is tirzepatide?
The Zepbound label describes tirzepatide as "a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist" [1]. The Mounjaro label uses the same description [2]. Both labels list an initial US approval year of 2022 [1][2].
The FDA approved Zepbound for chronic weight management on November 8, 2023, and noted at the time that tirzepatide was already approved under the trade name Mounjaro for blood sugar control in adults with type 2 diabetes [3]. On December 20, 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity [4].
The Zepbound label states that "coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended" [1]. In practice that means Mounjaro and Zepbound are the same molecule under two brand names, not two drugs to combine.
Tirzepatide is often compared with newer Lilly molecules that are still in trials. Our guide to retatrutide vs tirzepatide covers that comparison, and the retatrutide treatment page covers the investigational drug itself.
What is tirzepatide FDA approved for?
The current labels list four uses across the two brands. The wording below is taken from the labels on DailyMed, both revised in August 2026 [1][2].
Mounjaro: Indication as the label states it: "as an adjunct to diet and exercise to improve glycemic control" [2]; Who it covers: Adults and pediatric patients 10 years of age and older with type 2 diabetes
Mounjaro: Indication as the label states it: "to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke)" [2]; Who it covers: Adults with type 2 diabetes "who are at high risk for these events"
Zepbound: Indication as the label states it: "to reduce excess body weight and maintain weight reduction long term" [1]; Who it covers: Adults with obesity, or adults with overweight "in the presence of at least one weight-related comorbid condition"
Zepbound: Indication as the label states it: "to treat moderate to severe obstructive sleep apnea (OSA)" [1]; Who it covers: Adults with obesity
What is Mounjaro approved for?
Mounjaro's label lists glycemic control in type 2 diabetes for adults and for children 10 years and older, and reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events [2]. The label's Recent Major Changes section dates the pediatric indication to 12/2025 and the cardiovascular indication to 08/2026 [2].
What is Zepbound approved for?
Both Zepbound indications are "in combination with a reduced-calorie diet and increased physical activity" [1]. When the FDA announced the 2023 weight management approval, it defined obesity as a body mass index of 30 or greater and overweight as 27 or greater with at least one weight-related condition, such as high blood pressure, type 2 diabetes or high cholesterol [3].
How is tirzepatide given?
Both labels describe a subcutaneous injection once weekly, "at any time of day, with or without meals," in the abdomen or thigh, or in the back of the upper arm when another person gives it [1][2]. The labels say to rotate injection sites with each dose [1][2].
What forms does tirzepatide come in?
The labels list four presentations: prefilled single-dose pens, single-dose vials, multi-dose vials and single-patient-use KwikPens [1][2]. Single-dose pens and vials hold 0.5 mL at strengths from 2.5 mg to 15 mg; the multi-dose vial and the KwikPen each hold 2.4 mL and contain four 0.6 mL doses [1][2]. For vials, the labels mention a syringe "capable of measuring a 0.5 mL or 0.6 mL dose" and a new syringe and needle for each injection [1][2].
What is the tirzepatide dosing schedule on the label?
This is the schedule the FDA labels describe for prescribers, reproduced so you can read your own prescription against it. It is not a dosing recommendation; the prescriber sets the dose.
Starting dose: Zepbound label [1]: 2.5 mg once weekly for 4 weeks; "not approved as a maintenance dosage"; Mounjaro label [2]: 2.5 mg once weekly
Increases: Zepbound label [1]: To 5 mg after 4 weeks, then in 2.5 mg steps after at least 4 weeks on the current dose; Mounjaro label [2]: In 2.5 mg steps after at least 4 weeks on the current dose, "if additional glycemic control is needed"
Maintenance: Zepbound label [1]: 5, 10 or 15 mg weekly for weight; 10 or 15 mg weekly for sleep apnea; Mounjaro label [2]: Not split by indication
Maximum: Zepbound label [1]: 15 mg once weekly; Mounjaro label [2]: 15 mg once weekly in adults; 10 mg once weekly in pediatric patients
Both labels say the escalation is followed to reduce the risk of gastrointestinal adverse reactions [1][2]. For a missed dose, the labels instruct taking it within 4 days (96 hours), or otherwise skipping it and returning to the regular day [1][2]. To turn a prescribed dose into a volume or syringe reading, use our tirzepatide dosage calculator.
What did the tirzepatide clinical trials measure?
Lilly's trial programs for tirzepatide are named SURPASS (type 2 diabetes) and SURMOUNT (obesity and related conditions). The table summarizes the trials covered below; each result is the trial's own reported figure.
SURMOUNT-1 [5]: Population: 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes; Length: 72 weeks; Primary outcome reported: Mean weight change -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% placebo
SURPASS-2 [6]: Population: 1,879 adults with type 2 diabetes; Length: 40 weeks; Primary outcome reported: HbA1c change -2.01 to -2.30 points with tirzepatide vs -1.86 with semaglutide 1 mg
SURMOUNT-OSA [7]: Population: Adults with moderate to severe sleep apnea and obesity, two trials; Length: 52 weeks; Primary outcome reported: AHI change -25.3 and -29.3 events per hour vs -5.3 and -5.5 with placebo
SURMOUNT-5 [8]: Population: 751 adults with obesity, without type 2 diabetes; Length: 72 weeks; Primary outcome reported: Weight change -20.2% with tirzepatide vs -13.7% with semaglutide
SURPASS-CVOT [2]: Population: 13,299 adults with type 2 diabetes and established cardiovascular disease; Length: Median 210.1 weeks; Primary outcome reported: Hazard ratio 0.92 for major cardiovascular events vs dulaglutide
SURMOUNT-1: tirzepatide in adults with obesity
SURMOUNT-1 was a phase 3, double-blind trial that assigned 2,539 adults with a BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, to weekly tirzepatide 5 mg, 10 mg or 15 mg or placebo for 72 weeks, including a 20-week dose-escalation period [5]. Mean baseline weight was 104.8 kg [5].
The mean percentage change in weight at week 72 was -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, compared with -3.1% with placebo (treatment-regimen estimand) [5]. A weight reduction of 20% or more was recorded in 50% of the 10 mg group and 57% of the 15 mg group, compared with 3% of the placebo group [5]. Adverse events led to stopping treatment in 4.3%, 7.1% and 6.2% of the three tirzepatide groups and 2.6% of the placebo group [5].
SURPASS: tirzepatide in type 2 diabetes
SURPASS-1 was a 40-week double-blind trial in 478 adults with type 2 diabetes managed with diet and exercise alone [2]. The Mounjaro label reports a mean HbA1c change at week 40 of -1.8, -1.7 and -1.7 percentage points with 5 mg, 10 mg and 15 mg, compared with -0.1 with placebo [2].
SURPASS-2 was an open-label, 40-week phase 3 trial that randomized 1,879 adults with type 2 diabetes to tirzepatide 5 mg, 10 mg or 15 mg or semaglutide 1 mg [6]. The estimated mean HbA1c change was -2.01, -2.24 and -2.30 percentage points with the three tirzepatide doses and -1.86 with semaglutide [6]. The authors reported that tirzepatide at all doses was "noninferior and superior to semaglutide" on that measure [6].
SURPASS-PEDS randomized 99 patients aged 10 and older with type 2 diabetes to tirzepatide 5 mg, 10 mg or placebo for 30 weeks, with a 22-week open-label extension; it is the trial behind the pediatric indication on the Mounjaro label [2].
SURPASS-CVOT compared tirzepatide (up to 15 mg) with dulaglutide 1.5 mg in 13,299 adults with type 2 diabetes and established cardiovascular disease [2]. Over a median follow-up of 210.1 weeks, the label reports a hazard ratio for a first major adverse cardiovascular event of 0.92 (95.3% CI 0.83 to 1.01), states that tirzepatide was "non-inferior to dulaglutide," and adds that "superiority to dulaglutide was not established" [2].
SURMOUNT-OSA: tirzepatide and obstructive sleep apnea
SURMOUNT-OSA was two phase 3, double-blind trials in adults with moderate to severe obstructive sleep apnea and obesity: trial 1 enrolled people not using positive airway pressure (PAP) and trial 2 enrolled people on PAP [7]. Participants received the maximum tolerated dose of tirzepatide, 10 mg or 15 mg, or placebo for 52 weeks, and the primary end point was the change in the apnea-hypopnea index (AHI), the number of breathing pauses and shallow breaths per hour of sleep [7].
Mean baseline AHI was 51.5 events per hour in trial 1 and 49.5 in trial 2 [7]. At week 52 the mean AHI change was -25.3 events per hour with tirzepatide and -5.3 with placebo in trial 1, and -29.3 versus -5.5 in trial 2 [7]. The Zepbound label notes that the trials "did not evaluate the timing or appropriateness of PAP discontinuation" in people already using PAP [1].
SURMOUNT-5: tirzepatide vs semaglutide head to head
SURMOUNT-5 was a phase 3b, open-label trial that randomly assigned 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), injected weekly for 72 weeks [8]. The least-squares mean weight change at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide, and the mean change in waist circumference was -18.4 cm and -13.0 cm (P<0.001 for both) [8]. The trial was funded by Eli Lilly [8]. Our semaglutide vs tirzepatide guide covers the two drugs side by side.
What is the boxed warning for tirzepatide?
Both labels carry a boxed warning titled "Risk of Thyroid C-Cell Tumors" [1][2]. The Zepbound label's full boxed warning reads:
"In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND." [1]
The Mounjaro boxed warning uses the same wording with the brand name changed and opens "In both male and female rats" [2]. The full warnings, contraindications and adverse reactions are in each label's prescribing information [1][2].
How much does tirzepatide cost?
Prices below are what Lilly's own pages showed on November 20, 2026. Lilly states its offers can change at any time, so check the date and the source before you rely on a figure.
What is the list price of Mounjaro and Zepbound?
Lilly's pricing page gives the list price of Mounjaro as $1,112.16 per fill [12] and the list price of Zepbound as "$499 - $1,086.37 per fill," citing wholesale acquisition cost data accessed January 1, 2026, with a monthly supply defined as 28 days [11]. List price is what Lilly charges wholesalers; Lilly notes that what patients pay depends largely on insurance [11].
How much is Zepbound through LillyDirect without insurance?
LillyDirect, Lilly's own pharmacy channel, lists these monthly self-pay prices for Zepbound single-dose vials and the single-patient-use KwikPen [9]:
2.5 mg (starting dose): Self-pay price per month: $299; Price if not refilled within 45 days: $299
5 mg: Self-pay price per month: $399; Price if not refilled within 45 days: $399
7.5 mg: Self-pay price per month: $449; Price if not refilled within 45 days: $499
10 mg: Self-pay price per month: $449; Price if not refilled within 45 days: $699
12.5 mg: Self-pay price per month: $449; Price if not refilled within 45 days: $699
15 mg: Self-pay price per month: $449; Price if not refilled within 45 days: $699
The $449 price for 7.5 mg and above applies under the Zepbound Journey Program when each refill is completed within 45 days of the previous delivery; otherwise the regular prices in the right column apply [9][13]. Vials need a separate needle and syringe purchase, and the KwikPen needs pen needles [9]. These prices took effect in December 2025, when Lilly cut the 2.5 mg price from $349 to $299 and the 5 mg price from $499 to $399 [15].
How much is Mounjaro without insurance?
LillyDirect lists Mounjaro single-dose pens for self-pay "starting at $499/month" at every strength from 2.5 mg to 15 mg [10].
Is there a savings card for Zepbound or Mounjaro?
With commercial insurance that covers the drug, Lilly's savings cards let eligible patients pay "as little as $25" for a one-, two- or three-month fill of single-dose pens [13][14]. The Zepbound card caps savings at $100 per one-month fill and $1,300 per calendar year, and its terms say the card "expires and savings end on 12/31/2026" [13]. The Mounjaro card caps savings at $150 per one-month fill [14]. The savings card terms exclude people enrolled in government-funded programs, including Medicare and Medicaid [13][14]. For Medicare Part D patients prescribed Zepbound for weight management, Lilly's page describes coverage through a Medicare GLP-1 Bridge "for no more than $50/month," with terms applying [13].
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. The FDA states that "compounded drugs are not FDA approved," which means the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed" [16]. Mounjaro and Zepbound are the FDA-approved products described on this page. The FDA declared the tirzepatide injection shortage resolved on December 19, 2024 [17], which changed the rules for compounders. The history, the current FDA policy and what compounded tirzepatide studies measured are covered on our compounded tirzepatide page.
How do I find a clinic that prescribes tirzepatide?
Mounjaro and Zepbound are prescription medicines, so you need a licensed prescriber, either in person or by telehealth, and a licensed pharmacy to fill the prescription. A clinic that lists tirzepatide may prescribe the brand product, a compounded preparation, or both; ask which before you book.
What should I check before I book?
The prescriber's license. Ask for the prescriber's full name and credentials and confirm an active license in your state with your state's medical or nursing board.
The pharmacy's license. The FDA's BeSafeRx page links to state board of pharmacy license databases and advises that a legitimate online pharmacy requires a prescription, has a US physical address and phone number, and has a licensed pharmacist to answer questions [18].
Brand or compounded. Ask whether the prescription is for Mounjaro, Zepbound or a compounded preparation, and which pharmacy fills it.
What should I ask a tirzepatide clinic?
Which product will you prescribe, and which FDA-labeled indication does it fall under?
Will the prescription go to LillyDirect, a retail pharmacy, or a compounding pharmacy?
What does the visit cost, and is the medicine billed separately from the visit or membership fee?
Who reviews my medical history against the label's contraindications, including the boxed warning?
How are dose changes and follow-up visits handled, and who do I contact between visits?
Do you help with insurance prior authorization or the Lilly savings programs?
Where can I find tirzepatide clinics on Regenerated.com?
Regenerated.com lists 499 clinics whose own websites name tirzepatide as a service, checked November 20, 2026. Browse tirzepatide clinics on Regenerated.com by state and city. A listing reflects what the clinic's website says; it is not an endorsement, and it does not confirm which tirzepatide product a clinic prescribes. Confirm licensure and the product with the clinic directly.